RBC Capital Maintains Outperform on Pliant Therapeutics, Lowers Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Pliant Therapeutics (NASDAQ:PLRX) but lowers the price target from $54 to $45.

May 07, 2024 | 3:14 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital has maintained its Outperform rating on Pliant Therapeutics but reduced the price target from $54 to $45.
While the reduction in price target could suggest a tempered outlook on the stock's short-term price potential, the maintenance of an Outperform rating indicates a continued positive view on the company's fundamentals and long-term prospects. This mixed signal could lead to neutral short-term price movement as investors weigh the lowered price target against the reaffirmed positive rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100